Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Article

Ixabepilone

Alisha Stein
CJON 2010, 14(1), 65-71 DOI: 10.1188/10.CJON.65-71

Patterns of breast cancer care continue to be amended because of the more frequent use of anthracyclines and taxanes in earlier lines of therapy (particularly in the adjuvant setting) and the emergence of multidrug resistance. When treating women with recurrent or metastatic breast cancer that is resistant to anthracyclines and taxanes, nurses have a unique opportunity to foster a sense of hope by helping patients understand available treatment options and what to expect during therapy. This article presents information on the use of an epothilone agent, ixabepilone (Ixempra®, Bristol-Myers Squibb), a new treatment option for metastatic breast cancer after anthracycline and taxane failure. The information will allow nurses and their patients to collaborate as a team to help prevent or effectively manage side effects. In addition, nurses can take a proactive approach in educating patients about treatment options to enhance their quality of life.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or